<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30362666</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>20</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1098-1004</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>26</Day>                    </PubDate>                </JournalIssue>                <Title>Human mutation</Title>                <ISOAbbreviation>Hum. Mutat.</ISOAbbreviation>            </Journal>            <ArticleTitle>Novel POLE pathogenic germline variant in a family with multiple primary tumors results in distinct mutational signatures.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/humu.23676</ELocationID>            <Abstract>                <AbstractText>We describe a family in which four siblings exhibited multiple or classic colonic polyposis with or without colorectal carcinoma (CRC). One female developed three primary tumors, including CRC and carcinomas of the ovary and breast. Whole-exome sequencing of germline DNA from affected and unaffected individuals revealed a novel missense mutation in the exonuclease domain of POLE (c.833C&gt;A; p.Thr278Lys) associated with a highly penetrant, autosomal-dominant inheritance pattern. Functional studies in yeast and demonstration of a high mutational burden in the available tumors confirmed the pathogenicity of the novel variant. Prominent POLE-deficient somatic mutational signatures were seen in the CRCs, but in contrast, a mutational signature typical of concomitant tumoral loss of POLE and mismatch-repair function (POLE-exo<sup>*</sup> /MSI) was noted in the breast cancer. The breast cancer also showed distinctive pathological characteristics that reflect the presence of both the germline POLE variant and the secondary somatic MMR alterations.</AbstractText>                <CopyrightInformation>© 2018 Wiley Periodicals, Inc.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Castellsagué</LastName>                    <ForeName>Ester</ForeName>                    <Initials>E</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-1298-9971</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Human Genetics, McGill University, Montreal, Quebec, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medical Genetics, The Lady Davis Institute, Segal Cancer Centre, Jewish General Hospital, Montreal, Quebec, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Translational Research Laboratory, Catalan Institute of Oncology, IDIBELL, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Rui</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>McGill University and Génome Québec Innovation Centre, Montreal, Quebec, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Aligue</LastName>                    <ForeName>Rosa</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Biomedical Sciences Department, School of Medicine, University de Barcelona, IDIBAPS, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>González</LastName>                    <ForeName>Sara</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sanz</LastName>                    <ForeName>Judit</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Genetic Counselling Unit, Hospital Universitari de Vic, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Martin</LastName>                    <ForeName>Edgar</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Biomedical Sciences Department, School of Medicine, University de Barcelona, IDIBAPS, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Velasco</LastName>                    <ForeName>Àngela</ForeName>                    <Initials>À</Initials>                    <AffiliationInfo>                        <Affiliation>Hereditary Cancer Program, Catalan Institute of Oncology, IDIBGI, Girona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Capellá</LastName>                    <ForeName>Gabriel</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Stewart</LastName>                    <ForeName>Colin J R</ForeName>                    <Initials>CJR</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Histopathology, King Edward Memorial Hospital, and School for Women's and Infants' Health, University of Western Australia, Perth, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Vidal</LastName>                    <ForeName>August</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Hospital de Bellvitge, CIBERONC, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Majewski</LastName>                    <ForeName>Jacek</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>McGill University and Génome Québec Innovation Centre, Montreal, Quebec, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rivera</LastName>                    <ForeName>Barbara</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medical Genetics and Cancer Research Program, Research Institute McGill University Health Centre, Montreal, Quebec, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Polak</LastName>                    <ForeName>Paz</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Icahn School of Medicine at Mount Sinai, Department of Oncological Sciences, Mount Sinai Hospital, New York City, New York.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Matias-Guiu</LastName>                    <ForeName>Xavier</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Hospital de Bellvitge, CIBERONC, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Brunet</LastName>                    <ForeName>Joan</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Hereditary Cancer Program, Catalan Institute of Oncology, IDIBGI, Girona, Spain.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Medical Sciences Department, School of Medicine, University of Girona, Girona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Foulkes</LastName>                    <ForeName>William D</ForeName>                    <Initials>WD</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-7427-4651</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Human Genetics, McGill University, Montreal, Quebec, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medical Genetics, The Lady Davis Institute, Segal Cancer Centre, Jewish General Hospital, Montreal, Quebec, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medical Genetics and Cancer Research Program, Research Institute McGill University Health Centre, Montreal, Quebec, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Program in Cancer Genetics, Department of Oncology and Human Genetics, McGill University, Montreal, Quebec, Canada.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>PIOF-GA-2012-327193</GrantID>                    <Agency>Marie Curie International Outgoing Fellowship</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>FDN-148390</GrantID>                    <Agency>Canadian Institutes of Health Research</Agency>                    <Country>Canada</Country>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>26</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Hum Mutat</MedlineTA>            <NlmUniqueID>9215429</NlmUniqueID>            <ISSNLinking>1059-7794</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">POLE</Keyword>            <Keyword MajorTopicYN="N">PPAP</Keyword>            <Keyword MajorTopicYN="N">colorectal cancer</Keyword>            <Keyword MajorTopicYN="N">genetic diagnosis</Keyword>            <Keyword MajorTopicYN="N">hereditary cancer</Keyword>            <Keyword MajorTopicYN="N">mutational signatures</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>06</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>20</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30362666</ArticleId>            <ArticleId IdType="doi">10.1002/humu.23676</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>